Status message

Not the entire site translated, but only to "Journal"

Clinically Relevant Drug Interactions in the Treatment of Second-Generation Antipsychotics

Moscow Research Institute of Psychiatry – the branch of the V. Serbsky National Medical Research Center for Psychiatry and Narcology, Moscow, Russia

SUMMARY:
The article provides a review of the literature on the problem of drug interactions among modern antipsychotics. Clinically significant pharmacokinetic and pharmacodynamic interactions of second-generation antipsychotics with psychotropic and somatotropic agents during combined pharmacotherapy are described. The mechanisms underlying the occurrence of drug interactions are disclosed. It has been shown that most often drug interactions occur at the metabolic level with the participation of isoenzymes CYP1A2, CYP2D6 and CYP3A4. Potent inhibitors of CYP3A4 (fluvoxamine and fluoxetine) and CYP2D6 (fluoxetine and paroxetine) can slow down the metabolism of antipsychotics and lead to the development of side effects. Particular attention is paid to the problem of pharmacodynamic interactions associated with prolongation of the QT interval. A list of somatotropic drugs is presented, the appointment of which should be avoided in conjunction with second-generation antipsychotics in order to prevent the development of cardiac arrhythmias.
CONTACT: Malin D.I., doctormalin@gmail.com
CITATION: Malin D.I., Ryvkin P.V. Clinically Relevant Drug Interactions in the Treatment of Second-Generation Antipsychotics // Sovrem. ter. psih. rasstrojstv [Current Therapy of Mental Disorders]. – 2021. – No. 2. – Pр. 36–45. – DOI: 10.21265/PSYPH.2021.57.2.005
CONFLICT OF INTEREST: the authors declare no conflict of interest.
 

It appears your Web browser is not configured to display PDF files. Download adobe Acrobat or click here to download the PDF file.

References: 

1.    Mosolov S.N. Osnovy psikhofarmakoterapii. – M: Vostok, 1996. – 288 s. 
2.    Neznanov N.G., Mosolov S.N., Ivanov M.V. Psikhofarmakoterapiya // Psikhiatriya: natsional'noe rukovodstvo / pod red. N.G. Neznanova, Yu.A. Aleksandrovskogo. – M.: GEOTAR-Media, 2018. – S. 820–893.
3.    Psikhiatriya: spravochnik prakticheskogo vracha / pod red. A.G. Gofmana. Izd. 2. – M.: MEDpress-inform, 2010. – 592 s. 
4.    Mosolov S.N., Kapiletti S.G., Tsukarzi E.E. Antipsikhoticheskaya farmakoterapiya shizofrenii: ot nauchnykh dannykh k klinicheskim rekomendatsiyam // Biologicheskie metody terapii psikhicheskikh rasstroistv. Dokazatel'naya meditsina – klinicheskoi praktike / pod red. S.N. Mosolova. – M.: Sotsial'no-politicheskaya mysl', 2012. – S. 11–60. 
5.    Mosolov S.N., Kalinin V.V., Eremin A.V. Sravnitel'naya effektivnost' i perenosimost' novogo pokoleniya antipsikhoticheskikh sredstv pri lechenii obostrenii shizofrenii (metaanaliz original'nykh issledovanii olanzapina, risperidona, kvetiapina, klozapina i galoperidola) // Novye dostizheniya v terapii psikhicheskikh zabolevanii. – M.: BINOM. Laboratoriya znanii, 2002. – S. 82–94.
6.     Spina E., Scordo M., D’Arrigo C. Metabolic drug interaction with new psychotropic agents // Blackwell Publishing Fundamental and Clinical Pharmacology. – 2003. – Vol. 17. – P. 517–538. 
7.    Federal'noe rukovodstvo po ispol'zovaniyu lekarstvennykh sredstv (formulyarnaya sistema) / pod red. A.G. Chuchalina, Yu.B. Belousova, V.V. Yasnetsova.  8-e izd., pererab. i dop.  M.: Ekho, 2007 (M.: Shcherbinskaya tipografiya).  1003 s.
8.    Kostyuk G.P., Shmukler A.B., Golubev S.A. i dr. Epidemiologicheskie aspekty diagnostiki shizofrenii v Moskve // Sotsial'naya i klinicheskaya psikhiatriya. – 2017. – № 3. – S. 5–9.
9.    Brett A., Dortch M., Ereshefsky L. et all. S.Clinically Significant Psychotropic Drug-Drug Interactions in the Primary Care Setting // Curr Psychiatry Rep. – 2012. – Vol. 14. – P. 376–390. 
10.    Baltkais Ya.Ya., Fateev V.A. Vzaimodeistvie lekarstvennykh sredstv. – M.: Meditsina, 1991. – 304 s. 
11.    Syunyakov T.S. Vzaimodeistviya lekarstvennykh sredstv pri antipsikhoticheskoi terapii shizofrenii: pravil'nye i riskovannye sochetaniya lekarstvennykh sredstv // Sovremennaya terapiya psikhicheskikh rasstroistv. – 2013. – № 1. – S. 11–17.
12.    Federal'noe rukovodstvo po ispol'zovaniyu lekarstvennykh sredstv (formulyarnaya sistema) / pod red. A. G. Chuchalina, V.V. Yasnetsova. – Vyp. XIII. – M.: Ekho, 2012. – 984 s.
13.    Spina E., Hiemke C., De Leon J. Assessing drug-drug interactions through therapeutic drug monitoring when administering oral second-generation antipsychotics // Expert Opin Drug MetabToxicol. – 2016. – Vol. 12 (4). – P. 407–422. 
14.    Fleeman N., Dundar Y., Dickson R. et al. Cytochrome P450 testing for prescribing antipsychotics in adults with schizophrenia: systematic review and meta-analyses // Pharmacogenomics J. – 2011. – Vol. 11. – P. 1–14. 
15.    Arranz M.J., Rivera M., Munro J.C. Pharmacogenetics of response to antipsychotics in patients with schizophrenia // CNS Drugs. – 2011. – Vol. 25. – P. 933–969. 
16.     Kapitany T., Meszaros K., Lenzinger E. et al. Genetic polymorphisms for drug metabolism (cyp2d6) and tardive dyskinesia in schizophrenia // Schizophr Res. – 1998. – Vol. 32. – P. 101–106. 
17.    Malin D.I. Pobochnoe deistvie psikhotropnykh sredstv. – M: Vuzovskaya kniga, 2000. – 207 s. 
18.    Spivak L.I., Raiskii V.A., Vilenskii B.S. Oslozhneniya psikhofarmakoterapii. – L.: Meditsina, 1988. – 168 s.
19.    Federal'noe rukovodstvo po ispol'zovaniyu lekarstvennykh sredstv (formulyarnaya sistema) / pod red. A.G. Chuchalina, Yu.B. Belousova, V.V. Yasnetsova. – Izd. 7-e, pererab. i dop. – M.: Ekho, 2006. 
20.    Naber D., Leppig M., Grohmann R., Hippius H. Efficacy and adverse effects of clozapine in the treatment of schizophrenia and tardive dyskinesia-a retrospective study of 387 patients // Psychopharmacology (Berl). – 1989. – Vol. 99. ( Suppl.). – P. 73–76.
21.    Mosolov S.N., Tsukarzi E.E. Psikhofarmakoterapiya shizofrenii // Psikhiatriya: Natsional'noe rukovodstvo / pod red. N.G. Neznanova, Yu.A. Aleksandrovskogo. – M.: GEOTAR-Media, 2018. – S. 578–633.
22.    Song S. Cardiotoxicity of antipsychoticdrugs: Abnormal ECG in 1266 cases // Chung Hua Shen Ching Shen Ko Tsa Chih. – 1989. – Vol. 22 (2). – P. 77–79. 
23.    Warner J., Barnes T., Henry J. Electrocardiographic changes in patients receiving neuroleptic medication // Acta Psychiatr Scand. – 1996. – Vol. 93 (4). – P. 311–313. 
24.    Glassman A, Bigger J. Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death // Am J Psychiat. – 2001. – Vol. 158. – P. 1774–1782.
25.    Volkov V.P. Kardiotoksichnost' fenotiazinovykh neiroleptikov (obzor literatury) // Psikhiatriya i psikhofarmakoterapiya. – 2010. – № 2. – S. 41–45.
26.    Aunsholt N.A. Prolonged Q-T interval and Hypokalemia by haloperidol // Acta Psychiatr Scand. – 1989. – Vol. 79 (4). – P. 411–420.
27.    Pfizer. Briefing document for ziprasidone HC1 presented at the FDA. – Psychopharmacological Drugs Advisory Committee. – July 19, 2000.
28.    Gottschalk E., Dinovo E., Biener R., Nandi B. Plasma concentrations of thioridazine metabolites and ECG abnormalities // J Pharm Sci. – 1978. – Vol. 67 (2). – P. 155–157.
29.    Metzger E., Friedman R. Prolongation of the corrected QT and torsades de pointes cardiac arrhythmia associated with intravenous haloperidol in the medically ill // J Clin Psychopharmacol. – 1993. – Vol. 13 (2). – P. 128–132.
30.    Nielsen J., Wang F., Graff C., Kanters J. QT dynamics during treatment with sertindole // Ther Adv Psychopharmacol. – 2015. – Vol. 5 (1). – P. 26–31.
31.    Hiroyoshi T.,TakefumiS.,Gary R. and Hiroyuki U. Antipsychotic polypharmacy and corrected QT interval: A systematic review // Can J Psychiatry. – 2015. – Vol. 60 (5). – P. 215–220.
32.    Reilly J.G., Ayis S.A., Ferrier IN. et al. QTc-interval abnormalities and psychotropic drug therapy in psychiatric patients // Lancet. – 2000. – Vol. 355. – P. 1048–1052. 
33.    Rosenzweig P., Canal M., Patat A. et al. A review of the pharmacokinetics, tolerability and pharmacodynamics of amisulpride in healthy volunteers // Human Psychopharmacology. – 2002. – Vol. 17, No. 1. – P. 1–13. 
34.    Daniel D.G., Saha A.R. Inenito G. et al. Aripiprazole, a novel antipsychotic: overview of a phase II study result // Int J Neuropsyhopharmacol. – 2000. – Vol. 3 (Suppl. 1). – P. 157–174.
35.    Liverpool Drug Interaction Group // Interactions with Experimental COVID-19 Therapies. – April, 9, 2020.
36.    Aung C.L., Brien J.C., Nien P.C et al. Increased aripiprazole concentration in an HIV - positive male concurrently taking duloxetine, darunavir and ritonavir // Ann Pharmacoter. – 2010. – Vol. 44 (11). – P. 1850–1854.
37.    Goodlet K.J., Zmarlicka M.T. and Peckham A.M. Drug-drug interaction and clinical considerations with co-administration of antiretrovirals and psychotropic drugs // CNS Spectrums. – 2018. – P. 1–26. 
38.    Leon J., Spina E. Possible Pharmacodynamic and Pharmacokinetic Drug-Drug Interactions That Are Likely to Be Clinically Relevant and/or Frequent in Bipolar Disorder // Current Psychiatry Reports. – 2018. – Vol. 20. – P. 17. 
39.    Prakash C., Kamel A., Cui D. et al.Identification of the major human liver cytochromeP450 isoform(s) responsible for the formation of theprimary metabolites of ziprasidone and prediction of possible drug interactions // Br J Clin Pharmacol. – 2000. – Vol. 49 (Suppl. 1). – P. 35–42.
40.    Miceli J.J., Anziano R.J., Robarge L. et al.The effect of carbamazepine on the steady-state pharmacokinetics of ziprasidone in healthy volunteers // British Journal of Clinical Pharmacology. – 2000. – Vol. 49 (Suppl. 1). – P. 65–70. 
41.    Miceli J.J., Smith M., Robarge L. et al. The effects of ketoconazole on ziprasidone pharmacokinetics—a placebo-controlled crossover study in healthy volunteers // British Journal of Clinical Pharmacology. – 2000. – Vol. 49 (Suppl. 1). – P. 71–76. 
42.    Komossa K., Rummel-Kluge C., Hunger H. et al. Ziprasidone versus other atypical antipsychotics for schizophrenia // Cochrane Database Syst Rev. – 2009. – Vol. 7 (4). – P. 81–90.
43.    Citrome L. Cariprazine: chemistry, pharmacodynamics, pharmacokinetics, and metabolism, clinical efficacy, safety, and tolerability // Expert Opinion on Drug Metabolism & Toxicology. – 2013. – Vol. 9, No. 2. – P. 193–206.
44.    Bazire S. Drug interaction // Psychotropic Drug Directory (The Professionals Pocket Handbook and Aide Memoire). – Quay Books Division. – 2002. – P. 223–230.
45.    Shen W.W. The metabolism of atypical antipsychotic drugs: an update // Ann Clin Psychiatry. – 1999. – Vol. 1. – P. 145–158. 
46.    Dev V., Raniwalla J. Quetiapine: a review of its safety in the management of schizophrenia // Drug Saf. – 2000. – Vol. 23. – P. 295–307.
47.    Wong Y.W.J., Yeh C., Thyrum P.T. The effects of concomitant phenytoin administration on the steady-state pharmacokinetics of quetiapine // J Clin Psychopharmacol. – 2001. – P. 2189–2193. 
48.    Eierman B., Engel G., Johansson I. et al. The involvement of CYP1A2 and CYP3A4 in the metabolismof clozapine // Br J Clin Pharmacol. – 1997. – Vol. 44. – P. 439–446. 
49.    Linnet K., Olesen O.V. Metabolism of clozapine by c DNA expressed human cytochrome P450 enzymes // Drug Metab Dispos. – 1997. – Vol. 25. – P. 1379–1382. 
50.    Taylor D. Pharmacokinetic interactions involving clozapine // Br J Psychiatry. – 1997. – Vol. 17. – P. 109–112. 
51.     Edge S.C., Markowitz J.S., DeVane C.L. Clozapine drug interactions: a review of the literature// Hum. Psychopharmacol.-1997.-Vol. 12. - P. 5–20. 
52.     Facciola` G., Avenoso A., Scordo G.M. et al. Small effects of valproic acid on the plasma concentrations of clozapine and its major metabolites in patients with schizophrenic or affective disorders // Ther Drug Monit. – 1999. – Vol. 21. – P. 341–345. 
53.     Longo L.P., Salzman C. Valproic acid effects on serum concentrations of clozapine and norclozapine // Am J Psychiatry. – 1995. – Vol. 152. – P. 650–654. 
54.     Iqbal M.M., Rahman A., Husain Z. et al. Clozapine: a clinical review of adverse effects and management // Ann Clin Psychiatry. – 2003. – Vol. 15. – P. 33–48.
55.     Lieberman J.A. Maximizing clozapine therapy: managing side effects // J Clin Psychiatry. – 1998. – Vol. 59 (Suppl. 3). – P. 38–43. 
56.     Blake L.M., Marks R.C., Luchins D.J. Reversible neurologic symptoms with clozapine and lithium // J Clin Psychopharmacol. – 1992. – Vol. 12 (4). – P. 297–299. 
57.     Citrome L. Lurasidone for schizophrenia: a brief review of a new second-generation antipsychotic // Clin Schizophr Relat Psychoses. – 2011. – Vol. 4, No. 4. – P. 251–257. 
58.    Greenberg W.M., Citrome L. Pharmacokinetics and pharmacodynamics of Lurasidone Hydrochloride, a Second-generation antipsychotic: A systematic review of the published literatur // Clin Pharmacokinet. –2017. – Vol. 56 (5). – P. 493–503. 
59.    Kassahun K., Mattiuz E., Nyhart E. et al. Disposition and biotransformation of the antipsychotic agent olanzapine inhumans // Drug Metab Dispos. – 1997. – Vol. 25. – P. 81–93. 
60.    De Jong J., Hoogenboom B., van Troostwijck L.D., De Hann L. Interaction of olanzapine with fluvoxamine // Psychopharmacology. – 2001. – Vol. 156. – P. 219–220. 
61.    Hiemke C., Avi P., Jabarin M. et al. Fluvoxamine augmentation of olanzapine in chronic schizophrenia: pharmacokinetic interactions and clinical effects // J Clin Psychopharmacol. – 2002. – Vol. 22. – P. 502–506. 
62.    Markowitz J.S., DeVane C.L. Suspected ciprofloxacin inhibition of olanzapine resulting in increased plasma concentrations // J Clin Psychopharmacol. – 1999. – Vol. 19. – P. 289–291. 
63.     Gossen D., de Suray J.M., Vandenhende F., Onkelinx C., Gangji D. Influence of fluoxetine on olanzapine pharmacokinetics // AAPS Pharm Sci. – 2002. – Vol. 4. – P. 11–16. 
64.    Callaghan J.T., Bergstrom R.F., Ptak L.R., Beasley C.M. Olanzapine: Pharmacokinetic and pharmacodynamic profile // Clin Pharmacokinet. – 1999. – Vol. 37. – P. 177–193. 
65.     Lucas R.A., Gilfillan D.J., Bergstrom R.F. A pharmacokinetic interaction between carbamazepine and olanzapine: observationson possible mechanisms // Eur J Clin Pharmacol. – 1998. – Vol. 54. – P. 639–643. 
66.     Olesen O.V., Linnet K. Olanzapine serum concentrations in psychiatric patients given standard doses: the influence of comedication // Ther Drug Monit. – 1999. – Vol. 21. – P. 87–90. 
67.     Penzak S.R., Hon Y.Y., Lawhorn W.D. et al. Influence of ritonavir on olanzapine pharmacokinetics in healthy volunteers // J Clin Psychopharmacol. – 2002. – Vol. 22. – P. 366–370. 
68.    Citrome L. Oral paliperidone extended-release: chemistry, pharmacodynamics, pharmacokinetics and metabolism, clinical efficacy, safety and tolerability // Expert Opinion on Drug Metabolism and Toxicology. – 2012. – Vol. 8. – P. 873–888. 
69.    Fang J., Bourin M., Baker G.B. Metabolism of risperidone to 9-hydroxyrisperidone by human cytochrome P450 2D6 and3A4 // Naunyn Schmiederbergs Arch. Pharmacol. -1999.-Vol. 359.-P.147–151. 
70.     Yasui-Furukori N., Hidestrand M., Spina E. et al. Different nantioselective 9-hydroxylation of risperidone by the two human CYP2D6 and CYP3A4 enzymes // Drug Metab Dispos. – 2001. – Vol. 29. – P. 1263–1268. 
71.     Huang M.L., Van Peer A., Woestenborghs R. et al. Pharmacokinetics of the novel antipsychotic agent risperidone and the prolactin response in healthy subjects // Clin Pharmacol Ther. – 1993. – Vol. 54. – P. 257–268. 
72.     Scordo M.G., Spina E., Facciola` G. at al. Cytochrome P450 2D6 genotype and steady-stateplasma levels of risperidone and 9-hydroxyrisperidone // Psychopharmacology. – 1999. – Vol. 147. – P. 300–305. 
73.     DeVane C.L., Nemeroff C.B. An evaluation of risperidone drug interactions // J Clin Psychopharmacol. – 2001. – Vol. 21. – P. 408–416. 
74.     Bondolfi G., Eap C.B., Bertschy G. et al. The effect of fluoxetine on the pharmacokinetics and safety of risperidone in psychiatric patients // Pharmacopsychiatry. – 2002. – Vol. 35. – P. 50–56. 
75.     Spina E., Avenoso A., Facciola` G, et al. Plasma concentrations of risperidone and 9-hydroxyrisperidone during combined treatment with paroxetine // Ther Drug Monit. – 2001. – Vol. 23. – P. 223–227. 
76.     Spina E., Avenoso A., Scordo M.G. et al. Inhibition of risperidone metabolism by fluoxetine in patients with schizophrenia: a clinically relevant pharmacokinetic drug interaction // J Clin Psychopharmacol. – 2002. – Vol. 22. – P. 419–423. 
77.    Amchin J., Zarycransky W., Taylor K.P. et al. Effect of venlafaxine on the pharmacokinetics of risperidone // J Clin Pharmacol. – 1999. – Vol. 39. – P. 297–309. 
78.     Sommers D.K., Snyman J.R., van Wyk M. et al. Lack of effect of amitriptyline on risperidone pharmacokinetics in schizophrenic patients // Int Clin Psychopharmacol. – 1997. – Vol. 12. – P. 141–143.
79.     De Leon J., Bork J. Risperidone and cytochrome P450 3A // J Clin Psychiatry. – 1997. – Vol. 58. – P. 450. 
80.     Spina E., Scordo M.G., Avenoso A, Perucca E. Adverse drug interaction between risperidone and carbamazepine in a patient with chronic schizophrenia and deficient CYP2D6 activity // J Clin Psychopharmacol. – 2001. – Vol. 21. – P. 108–109. 
81.     Spina E., Zoccali R. Sertindole: pharmacologicaland clinical profile and role in the treatment of schizophrenia // Expert Opin Drug MetabToxico. – 2008. – Vol. 4. – P. 629–638. 
82.     Lindstrom E., Farde L., Eberhard L., Haverkamp W. QTc interval prolongation and antipsychotic drug treatments: focus on sertindole // Int J Neuropsychopharmacol. – 2005. – Vol. 8. – P. 615–629.